ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors
April 22 2022 - 6:34AM
Business Wire
ChromaDex Corp. (NASDAQ: CDXC) today announced that it has
appointed two new members to its Board of Directors: Kristin
Patrick, Executive Vice President and Chief Marketing Officer of
Claire's Inc., and Ann Cohen, Executive Vice President and Chief
Financial Officer of The Institute of Internal Auditors (The
IIA).
“We welcome Ms. Patrick and Ms. Cohen to our distinguished
ChromaDex Board of Directors,” said Rob Fried, CEO of ChromaDex.
“Ms. Patrick has overseen some of the world’s most recognizable and
respected consumer brands, and Ms. Cohen is an executive with
significant financial expertise and of strong personal integrity.
We are excited and honored to be working with them both.”
As the Executive Vice President and Chief Marketing Officer at
Claire’s Inc., Ms. Patrick is part of the executive team leading
the transformation of the youth culture brand. Prior to joining
Claire’s Inc., Ms. Patrick was the Senior Vice President and Chief
Marketing Officer of Brand Strategy & Development at PepsiCo
where she was responsible for long-term brand vision across the
PepsiCo portfolio. Additionally, as the Chief Marketing Officer at
Playboy Enterprises, Ms. Patrick was responsible for ushering the
brand into a new era and rebuilding relevancy including developing
the brand architecture, positioning, and implementing a new
business strategy across all businesses.
Ms. Patrick’s 20+ year career spans multiple industries such as
fashion, omnichannel retail, entertainment, Consumer Packaged
Goods, beauty and includes expertise across food, drug, convenience
mass, luxury, mid-tier and Direct to Consumer channels. In addition
to Claire’s Inc., PepsiCo and Playboy Enterprises, she has held
positions at Disney, Calvin Klein, Gap, Inc., Revlon, and Liz
Claiborne. Ms. Patrick has developed a distinguished reputation for
being a disruptive, trend-setting brand steward, general manager,
and strategist.
At The IIA, Ms. Cohen oversees all financial, risk management,
and information technology and is both a Certified Public
Accountant (Florida) and a Certified Global Management Accountant.
Prior to joining The IIA, Ms. Cohen served in senior financial
leadership roles for both public and private companies including
Taylor Morrison Homes (formerly Taylor Woodrow), a $2.5 billion
international residential home builder, and Starwood Vacation
Ownership, a $600 million international division of Starwood Hotels
and Resorts.
In her career, Ms. Cohen has overseen financial reporting under
Generally Accepted Accounting Principles (GAAP) and International
Financial Reporting Standards (IFRS), business planning and
analysis, financial and operational strategies, human resources,
information technology, enterprise risk management, the acquisition
and disposition of projects, and regulatory reporting including SEC
reporting. Ms. Cohen has also worked closely with various public
accounting firms and audit committees.
Jeff Baxter and Caroline Levy resigned from the Board, and Kurt
Gustafson and Steve Block will not seek re-election to the Board at
the Company’s annual meeting for stockholders, expected to be held
in June 2022. ChromaDex thanks them all for their valuable
contributions.
For additional information on ChromaDex, visit
www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to the Company’s domestic and
international growth strategies and expected timing of the annual
meeting of stockholders. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects," "anticipates," "intends," "estimates," "plans,"
"potential," "possible," "probable," "believes," "seeks," "may,"
"will," "should," "could" or the negative of such terms or other
similar expressions. Risks that contribute to the uncertain nature
of these forward-looking statements include the impact of the
COVID-19 pandemic on our business and the global economy; our
history of operating losses and need to obtain additional
financing; the growth and profitability of our product sales; our
ability to maintain sales, marketing and distribution capabilities;
changing consumer perceptions of our products; our reliance on a
single or limited number of third-party suppliers; and the risks
and uncertainties associated with our business and financial
condition. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2021, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220422005137/en/
ChromaDex Media Contact: Kendall Knysch, Director of
Media Relations 310-388-6706 ext. 689 kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber, Vice
President of Finance and Investor Relations 949-419-0288 ext. 127
briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024